Literature DB >> 12355014

Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations.

Oded Gonen1, David M Moriarty, Belinda S Y Li, James S Babb, Juan He, John Listerud, Dina Jacobs, Clyde E Markowitz, Robert I Grossman.   

Abstract

PURPOSE: To quantify the rate of concentration decline of neuronal marker N-acetylaspartate (NAA) in the entire brain of patients with relapsing-remitting multiple sclerosis (MS) in relation to healthy age-matched control subjects.
MATERIALS AND METHODS: Whole-brain NAA (WBNAA) concentration was quantified in 49 patients with relapsing-remitting MS by using magnetic resonance (MR) imaging and proton MR spectroscopy. It was statistically analyzed by using Spearman rank correlation coefficients to test the intragroup relationship between WBNAA and Expanded Disability Status Scale (EDSS) score and Mann-Whitney analyses to test for differences between subgroups' EDSS scores versus previously published WBNAA values for healthy subjects, disease duration, and age.
RESULTS: Analyses indicated three subgroups of WBNAA dynamics: Ten patients' conditions were "stable," exhibiting an insignificant change of about 0% (0.02/14.37) per year of clinically definite disease duration (P =.54); 27 patients showed "moderate" decline, -2.8% (-0.34/12.18) per year (P <.01); and 12 patients experienced "rapid" decline, -27.9% (-3.39/12.14) per year (P <.01). No correlation was found between WBNAA deficit, EDSS score, and age.
CONCLUSION: Ascertaining an individual's NAA concentration dynamics might enable early forecast of disease course, reflect disease severity and thus influence treatment decisions, and improve clinical trial efficiency by allowing selection of candidates on the basis of WBNAA dynamics in addition to clinical status.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355014     DOI: 10.1148/radiol.2243011260

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  10 in total

Review 1.  Magnetic resonance spectroscopy in the monitoring of multiple sclerosis.

Authors:  Ponnada A Narayana
Journal:  J Neuroimaging       Date:  2005       Impact factor: 2.486

Review 2.  Multiple sclerosis: the role of MR imaging.

Authors:  Y Ge
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

3.  Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.

Authors:  D J Rigotti; A Gass; L Achtnichts; M Inglese; J S Babb; Y Naegelin; J Hirsch; M Amann; L Kappos; O Gonen
Journal:  Mult Scler       Date:  2011-09-15       Impact factor: 6.312

4.  Global N-acetylaspartate declines even in benign multiple sclerosis.

Authors:  D J Rigotti; O Gonen; R I Grossman; J S Babb; A Falini; B Benedetti; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-21       Impact factor: 3.825

5.  Reproducibility of three whole-brain N-acetylaspartate decline cohorts in relapsing-remitting multiple sclerosis.

Authors:  O Gonen; T A Oberndorfer; M Inglese; J S Babb; J Herbert; R I Grossman
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

Review 6.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 7.  Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders.

Authors:  D J Rigotti; M Inglese; O Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-05       Impact factor: 3.825

8.  Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.

Authors:  Elfar Adalsteinsson; Annette Langer-Gould; Ronald J Homer; Archana Rao; Edith V Sullivan; Christiane Abbehusen Lima; Adolf Pfefferbaum; Scott W Atlas
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

Review 9.  Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?

Authors:  Jae Young Lee; Kasra Taghian; Steven Petratos
Journal:  Acta Neuropathol Commun       Date:  2014-08-27       Impact factor: 7.801

Review 10.  Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker.

Authors:  Kelley M Swanberg; Karl Landheer; David Pitt; Christoph Juchem
Journal:  Front Neurol       Date:  2019-11-15       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.